

University of Dundee

## Analysis of throwing power for megasonic assisted electrodeposition of copper inside THVs

Jones, Thomas D. A.; Bernassau, Anne L.; Flynn, David; Price, Dennis; Beadel, Matthew; Desmulliez, Marc Phillippe Yves

*Published in:*  
Ultrasonics

*DOI:*  
[10.1016/j.ultras.2020.106111](https://doi.org/10.1016/j.ultras.2020.106111)

*Publication date:*  
2020

*Licence:*  
CC BY-NC-ND

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Jones, T. D. A., Bernassau, A. L., Flynn, D., Price, D., Beadel, M., & Desmulliez, M. P. Y. (2020). Analysis of throwing power for megasonic assisted electrodeposition of copper inside THVs. *Ultrasonics*, 104, 1-9. [106111]. <https://doi.org/10.1016/j.ultras.2020.106111>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## **Effect of Allopurinol on phosphocreatine recovery and muscle function in older people with impaired physical function – a randomised controlled trial**

### **Abstract**

#### **Background**

Allopurinol has vascular antioxidant effects and participates in purinergic signalling within muscle. We tested whether allopurinol could improve skeletal muscle energetics and physical function in older people with impaired physical performance.

#### **Methods**

We conducted a randomised, double blind, parallel group, placebo-controlled trial, comparing 20 weeks of allopurinol 600mg once daily versus placebo. We recruited community-dwelling participants aged 65 and over with baseline six-minute walk distance of <400m and no contraindications to MRI scanning. Outcomes were measured at baseline and 20 weeks. The primary outcome was post-exercise phosphocreatine recovery rate measured using  $^{31}\text{P}$  magnetic resonance spectroscopy of the calf. Secondary outcomes included six-minute walk distance, short physical performance battery (SPPB), lean body mass measured by bioimpedance, endothelial function and quality of life.

#### **Results**

124 participants were randomised, mean age 80 (SD 6) years. 59 (48%) were female, baseline six-minute walk distance was 293m (SD 80m) and baseline SPPB was 8.5 (SD 2.0).

Allopurinol did not significantly improve phosphocreatine recovery rate (treatment effect

0.10 units [95%CI -0.07 to 0.27],  $p=0.25$ ). No significant changes were seen in endothelial function, quality of life, lean body mass or SPPB. Allopurinol improved six-minute walk distance (treatment effect 25m [95% 4 to 46,  $p=0.02$ ]). This was more pronounced in those with high baseline oxidative stress and urate.

## Conclusion

Allopurinol improved six-minute walk distance but not phosphocreatine recovery rate in older people with impaired physical function. Antioxidant strategies to improve muscle function for older people may need to be targeted at subgroups with high baseline oxidative stress.

Trial registration: ISRCTN03331094

Keywords: Allopurinol, physical performance, oxidative stress, skeletal muscle

## **Key points**

- Oxidative stress has been implicated in muscle dysfunction and allopurinol has been shown to reduce oxidative stress in other organ systems with clinical benefit.
- Allopurinol did not improve phosphocreatine recovery rate (a measure of skeletal muscle mitochondrial function)
- Six-minute walk distance improved by a small but clinically significant amount but other measures of physical performance were unchanged
- Future studies should target older people with high baseline levels of oxidative stress.

## Introduction

Impaired physical performance is common with increasing age, and reduction in skeletal muscle function (part of the syndrome of sarcopenia) is a key contributor to this decline. Improving impaired physical function and preventing decline in physical function are key goals in maintaining health and wellbeing for a wide range of older people. Although regular exercise has been shown to increase muscle strength and to slow functional decline [1], the majority of older people are sedentary and often unable or unwilling to contemplate adequate exercise participation [2]. Alternative strategies to improve physical function are required to minimise dependency and maximise independence.

Allopurinol is a purine analogue which has been used to prevent gout for decades. It is a powerful inhibitor of xanthine oxidoreductase in both its forms – as xanthine dehydrogenase and as xanthine oxidase (XO). Inhibition of this key enzyme in the degradation of purines to urate lowers both urate as well as reactive oxygen species (ROS) which is a by-product of XO catalytic action. There are three reasons why allopurinol might be beneficial in ageing muscle. Firstly, skeletal muscle is particularly susceptible to oxidative stress mainly due to the rapid flux of oxygen and the balance of energy supply/demand. Previous studies have shown that oxidative stress is implicated in reduced quadriceps endurance [3]. Xanthine oxidase is a major generator of free radicals; up-regulation of xanthine oxidase and increased oxidative stress are found in ageing muscles and this mechanism has been implicated in sarcopenia [4]. Therefore reducing muscle oxidative damage might be expected to result in reduced muscle dysfunction, increased muscle contractile efficiency and reduced functional impairment.

Secondly, animal studies have previously demonstrated that allopurinol decreased free ADP levels needed to drive ATP synthesis, and normalised muscle phosphocreatine (PCr)-to-ATP

ratio (PCr/ATP) [5]. These findings would be compatible with a beneficial effect of allopurinol on mitochondrial function, perhaps due to the reduction in oxidative stress described above. Suppression of Xanthine Oxidase (XO) with allopurinol has indeed been shown to increase maximal isometric force in plantar flexion in animal models [6], and allopurinol use was associated with greater functional gains in older patients undergoing rehabilitation in an observational study [7].

Thirdly, we have previously shown that allopurinol improves vascular endothelial function in various intervention studies enrolling older people with established cardiometabolic disease [8-11]. An improvement in muscle perfusion could also potentially improve muscle function, particularly given the high prevalence of vascular dysfunction found in older people.

Therefore, we conducted this present study in older people with functional impairment to determine whether treatment with allopurinol could improve physical function, and to study the mechanism by which it might achieve this. We hypothesised that allopurinol would improve the initial rate of skeletal muscle phosphocreatine recovery after exercise (a measure of mitochondrial function) compared to placebo.

## **Methods**

### *Study design*

We performed a randomised, double-blinded, parallel-group, placebo-controlled trial between February 2016-August 2017. Ethics approval was obtained from East of Scotland Research Ethics committee (approval number 14/ES/1092), and regulatory approval was obtained from the Medicines and Healthcare products Regulatory Agency (Clinical Trials Authorisation 2014-004122-18). It was carried out in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants at the screening visit. The trial was funded by Dunhill Medical Trust (Grant Ref: R315/1113) and trial management support was

provided by Tayside Clinical Trials Unit. The trial was registered at [www.isrctn.com](http://www.isrctn.com) (ISRCTN03331094).

### *Population and recruitment*

Participants were eligible if they were aged 65 or over, with a six minute walk distance of <400m based on the study conducted by Newman et al [12]. Exclusion criteria were conditions likely to provide alternative causes for poor exercise tolerance and muscle dysfunction: a documented history of peripheral arterial disease, severe heart failure (left ventricular ejection fraction <35%), malignancy under active treatment, severe COPD, or long-term use of steroids (prednisolone equivalent of 10mg/day or more). Other exclusion criteria were for safety reasons: intolerance to allopurinol, any use of allopurinol within the last 30 days, current use of azathioprine, 6-mercaptopurine or theophyllines, or an estimated Glomerular Filtration Rate (eGFR) of 30ml/min/1.73m<sup>2</sup> or less. Participants unable to perform the short physical performance battery or six minute walk tests without human assistance were excluded, as were those with contraindications to MRI scanning, cognitive impairment precluding giving written informed consent, those who had participated in another clinical drug trial within the preceding 30 days and those with active acute gout. Participants were recruited via hospital outpatient clinics, newspaper advertisements to the local community, and from primary care practice database searches conducted by the NHS Research Scotland Primary Care Network (NRSPCN).

### *Intervention and comparator*

Matching capsules containing either 300mg of allopurinol or placebo that appeared identical (Tayside Pharmaceuticals, Dundee, UK) were dispensed in identical bottles which had no indication of treatment allocation. Participants took one capsule each day for the first four

weeks. If renal function remained stable and no side effects were noted, participants then took two capsules once a day for the remaining 16 weeks. Participants were permitted to continue their usual medication throughout the trial.

#### *Randomisation and allocation concealment*

Randomisation was performed in a 1:1 ratio by a web-based GCP compliant randomisation system (TRuST, Health Informatics Centre, University of Dundee) to ensure allocation concealment. A minimisation algorithm with a small random element was used to ensure balance across key baseline measures. Minimisation factors used were male vs female sex and baseline six-minute walk distance of < or >200m.

#### *Outcomes*

All outcomes were measured at baseline and at 20 weeks. Details of the methods used for outcomes measures are given in the Supplementary Information [13-20]. The pre-specified primary outcome was the initial rate of PCr recovery (ViPCR). Secondary outcomes were the six-minute walk distance [16], Short Physical Performance Battery [17], lean body mass derived from bioimpedance using the Sergi equation [18], endothelial function [19], and health-related quality of life measured using the EQ5D tool [20]. All outcomes were assessed by a research fellow blinded to intervention group, and investigators remained blinded to treatment allocation until after completion of the statistical analysis.

#### *Sample size calculation*

The sample size was calculated based on detecting a 20% difference between groups in the primary outcome of initial PCr resynthesis rate (ViPCR). Data published by Layec et al [3] showed ViPCR values in healthy older people ( $74 \pm 17$  %/min) vs COPD patients ( $52 \pm 13$



%/min) i.e. a 42% difference between healthy older people and patients with COPD. A conservative approach would be to assume that functionally impaired older people have less severe impairment than people with COPD. We therefore assumed 20% difference between healthy older people and functionally impaired older people on allopurinol. To detect this difference with 90% power at a significance level of  $\alpha=0.05$  requires 44 participants per group. Allowing for a 20% dropout rate, we required 110 participants. To ensure a further buffer against technical failure or uninterpretable MR spectroscopy results, the final sample size was set at 124 participants, which also gave sufficient power for key secondary endpoints to detect a 2% absolute difference in Flow-Mediated Dilatation of the brachial artery (FMD) [21] and the minimum clinically important difference of 20m for the six minute walk [22].

### *Analysis*

All analyses were performed using SPSS v24 (IBM, New York, USA) according to a pre-specified statistical analysis plan. A p value of  $<0.05$  was taken as significant for all analyses. Descriptive statistics were generated for both groups at baseline; comparisons between baseline groups were performed using Student's t-test for continuous variables if normally distributed, and Mann-Whitney U test for non-normally distributed variables. Categorical variables were compared using Pearson's chi-square test. The primary and secondary analyses were performed by modified intention to treat, including all participants with follow-up data. For normally distributed variables, general linear models were used to compare results between groups at 20 weeks, adjusted for baseline values. Several of the MRS variables were not normally distributed, but instead conformed to a gamma distribution. These variables were compared using generalised linear models, adjusting for baseline values of the variable under test, using a gamma distribution and log link function. Estimated

marginal means were generated to convey treatment effect size. Several sensitivity analyses were performed for the primary outcome. Multiple imputation (10 imputations) was performed using baseline ViPCr, age, sex, baseline six-minute walk distance and SPPB to impute missing ViPCr values. A per-protocol analysis was also performed, including only those participants still taking the full dose of study medication at the final visit, and with adherence >80%. Statistical analyses were performed blinded to treatment allocation, and unblinding of the analysis took place only after analysis completion.

## **Results**

265 individuals expressed interest in participating, of whom 142 attended a screening visit, and 124 were randomised. Baseline data on the randomised population are given in Table 1, and Figure 1 shows participant flow through the trial. A total of 116 individuals (58/62 in the allopurinol arm and 58/62 in the placebo arm) attended the final study visit. Adherence to the study medications was excellent; mean adherence in the allopurinol group was 93% (SD 12%), compared to 95% (SD 12%) in the placebo group ( $p=0.32$ ).

### *Primary Outcome*

There was no significant difference between the allopurinol and placebo groups in the initial rate of PCr recovery (ViPCR) corrected for baseline ViPCr. (Table 2)

### *Subgroup and sensitivity analyses:*

Pre-specified subgroup analyses for the primary outcome are shown in Supplementary Table 1. The only significant subgroup interaction was with baseline six-minute walk distance, where those with the lowest walk distance (<200m) showed deterioration in ViPCr with treatment, in contrast to those with a baseline walk distance of >300m ( $p=0.05$  for

interaction). For the per-protocol sensitivity analysis, a total of 98 participants were included (44 in the allopurinol arm and 54 in the placebo arm). Results for this analysis are shown in Table 2.

### *Secondary outcomes*

Non-MRS secondary outcomes are shown in Table 3. Allopurinol caused a large reduction in serum urate compared to the placebo group as expected. Six minute walk distance improved in the allopurinol group compared to placebo; the treatment effect (25m) was statistically significant and exceeded the minimum clinically important difference of 20m. Post-hoc exploratory subgroup analyses of the six minute walk distance suggested that the difference in 6MWT was significantly greater in participants who had higher baseline muscle oxidative stress (8-OHdG > 233ng/ml) and baseline urate (>0.41mmol/L) (Supplementary Table 2). A weak correlation ( $\rho=0.18$ ,  $p=0.06$ ) was seen between change in ViPCr and change in six-minute walk distance. Other measures of oxidative stress, endothelial function, physical performance, lean body mass and quality of life did not improve with allopurinol relative to placebo. Alternative MRS measures of muscle energetics are shown in Supplementary Table 3; no significant treatment effect was seen on any marker.

### *Adverse events*

Adverse events are shown aggregated into MedDRA system-organ-class categories in Supplementary Table 4. More adverse events were seen in the allopurinol arm, driven by a higher frequency of skin, gastrointestinal and vascular events.

## **Discussion**

The main finding from this present study is that allopurinol did not improve muscle efficiency as measured by initial rate of PCr recovery in older participants with functional impairment. However, it improved the 6MWT distance and this improvement was more pronounced in those with a higher baseline oxidative stress and urate level. This would suggest that the mechanism of improvement may not be by ADP-sparing and improved Phosphocreatine recycling but rather via an alternative antioxidant mechanism. We have previously demonstrated in a heart failure cohort that allopurinol at this high dose functions as an effective antioxidant, capable of abolishing Vitamin C-sensitive component of vascular oxidative stress [8]. Urate is an abundant and potent aqueous antioxidant in humans, although its importance as a major antioxidant *in vivo* is unclear [23,24]. It is possible that reducing urate in normouricemic patients with low background oxidative stress, who rely on urate for antioxidant defence, will negate any direct reduction in ROS generation by xanthine oxidase inhibition, leading to an overall null effect on oxidative stress, mitochondrial function and therefore PCr recovery. This could also explain the non-significant increase in 8OHdG we saw with treatment. This phenomenon has been previously demonstrated in another normouricemic cohort with low oxidative stress [25].

We found an increase in the secondary outcome of 6-minute walk test distance of 25m in the allopurinol group compared to placebo. Perera et al [22] suggest that a 20m gain in 6MWT is the minimum meaningful change in older people. In this present study, this difference in 6MWT was significantly greater in participants who had higher baseline muscle oxidative stress and baseline urate, which suggests that xanthine oxidase inhibition in these patients may be beneficial. The lack of effect of allopurinol on phosphocreatine recovery rate makes it unlikely that the improvement in six-minute walk distance was driven by improved mitochondrial function in normouricemic patients with low background oxidative stress. One

alternative explanation is that allopurinol may have exerted improvements in exercise capacity via adenosine receptors present in a variety of tissues including the heart and skeletal muscle; it is noteworthy that caffeine (a molecule in the xanthine family) is known to have beneficial effects on exercise capacity. It is also possible that the improvement in six-minute walk distance was a chance finding due to testing multiple secondary outcomes; this finding requires replication in future trials.

Future studies in older people should focus interventions in those with high baseline oxidative stress and hyperuricemia. Unlike previous studies in cohorts with established disease [8,26], we did not observe an improvement in vascular endothelial function in this cohort which suggests that any functional improvement seen in this study is not directly attributable to improvements in muscle blood flow. Markers of ATP depletion such as the rate constant  $k$ , Pi/PCr ratio and amount of  $\beta$ -ATP depletion post-exercise were not significantly different between groups indicating that ATP sparing may not be the mechanism by which allopurinol improved walk distance.

## Limitations

Preclinical work suggests that allopurinol might improve muscle function by reduction of XO-derived oxidative stress [6,27,28]. There are several reasons why we may not have detected this improvement in this present study. Only two men and no women met the clinical definition for sarcopenia and therefore it is possible that individuals with more impaired muscle physiology (i.e. those with sarcopenia) may have demonstrated greater improvement in muscle efficiency with allopurinol. The half-time recovery for phosphocreatine at baseline in our study was relatively preserved, suggesting that a ceiling effect may have limited the ability of allopurinol to improve measures of mitochondrial

function. A previous study showed that patients with sarcopenia have impaired endothelial function, a measure upon which allopurinol has repeatedly demonstrated a beneficial effect [29]. We deliberately used a high dose of allopurinol to be sure that XO-derived oxidative stress was completely abolished; previous dose-response work in patients with heart failure suggests that 600mg per day is required to achieve this [8]. The duration of therapy in our study was 20 weeks. It is possible but unlikely that a longer duration of action is required to demonstrate improvement in muscle efficiency if muscle oxidative stress reduction by XO inhibition is the mechanism by which it occurs. The positive effect on urate levels and improvement in six-minute walk distance argue in favour of this duration being long enough to produce relevant biological effects. Shorter durations of allopurinol therapy have shown improvements in endothelial function in previous studies [8,11], and as little as one week of allopurinol treatment improved skeletal muscle and mitochondrial function in preclinical models [6,30]. Muscle biopsies may have yielded more information on muscle oxidative stress but this option was declined by almost all patients and was therefore not pursued. Data acquisition for MR Spectroscopy commenced immediately post-exercise, potentially missing the very start of the recovery curve. Although we conducted the six-minute walk test only once at baseline and once at follow-up, the parallel-group design of our trial accounted for any learning effect, and thus the improvement in the allopurinol arm cannot be attributed to this.

In this present study, treatment allopurinol over 20 weeks did not improve muscle energetics as measured by MR spectroscopy. We observed a clinically relevant but modest increase in the 6MWT. Future studies could prospectively target those with sarcopenia, high urate and baseline muscle oxidative stress. Such an approach would be most likely to maximise the

efficacy of allopurinol and would stand the best chance of both confirming any effect on walk distance and of elucidating the mechanism of any such effect.

Acknowledgements: Professor Witham acknowledges support from the NIHR Newcastle Biomedical Research Centre

Conflicts of Interest: Allan D. Struthers has applied for a patent on the use of xanthine oxidase inhibitors to treat angina pectoris. All other authors have no conflicts of interest.

Funding: This work was supported by the Dunhill Medical Trust, grant R315/1113

## References

1. Lai CC, Tu YK, Wang TG, Huang YT, Chien KL. Effects of resistance training, endurance training and whole-body vibration on lean body mass, muscle strength and physical performance in older people: a systematic review and network meta-analysis. *Age Ageing* 2018;47:367-373.
2. McMurdo ME, Argo I, Crombie IK, Crombie IK, Feng Z, Sniehotta FF et al. Social, environmental and psychological factors associated with objective physical activity levels in the over 65s. *PLoS One* 2012;7:e31878.
3. Layec G, Haseler LJ, Hoff J, Richardson RS. Evidence that a higher ATP cost of muscular contraction contributes to the lower mechanical efficiency associated with COPD: preliminary findings. *Am J Physiol Regul Integr Comp Physiol* 2011;300:R1142-1147.
4. Sakellariou GK, Lightfoot AP, Earl KE, Stofanko M, McDonagh B. Redox homeostasis and age-related deficits in neuromuscular integrity and function. *J Cachexia Sarcopenia Muscle* 2017;8:881-906.
5. Lee J, Hu Q, Mansoor A, Kamdar F, Zhang J. Effect of acute xanthine oxidase inhibition on myocardial energetics during basal and very high cardiac workstates. *J Cardiovasc Transl Res* 2011;4:504-513.
6. Ryan MJ, Jackson JR, Hao Y, Leonard SS, Alway SE et al. Inhibition of xanthine oxidase reduces oxidative stress and improves skeletal muscle function in response to electrically stimulated isometric contractions in aged mice. *Free Radic Biol Med* 2011;51:38-52.
7. Beveridge LA, Ramage L, McMurdo ME, George J, Witham MD et al. Allopurinol use is associated with greater functional gains in older rehabilitation patients. *Age Ageing* 2013;42:400-404.



8. George J, Carr E, Davies J, Belch JJ, Struthers A et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation* 2006;114:2508-2516.
9. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. *J Am Coll Cardiol* 2013;61:926-932.
10. Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD et al. Allopurinol Reduces Left Ventricular Mass In Patients With Type 2 Diabetes And Left Ventricular Hypertrophy. *J Am Coll Cardiol* 2013;62:2284-2293.
11. Farquharson CAJ, Butler R, Hill A, Belch JJ, Struthers AD et al. Allopurinol improves endothelial dysfunction in chronic heart failure. *Circulation* 2002;106:221-226.
12. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. *J Am Medical Assoc* 2006;295:2018-2026.
13. Waters DL, Brooks WM, Qualls CR, Baumgartner RN. Skeletal muscle mitochondrial function and lean body mass in healthy exercising elderly. *Mech Ageing Dev* 2003;124:301-309.
14. Iotti S, Lodi R, Frassinetti C, Zaniol P, Barbiroli B. In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by <sup>31</sup>P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise. *NMR Biomed* 1993;6:248-253.

15. Naressi A, Couturier C, Castang I, de Beer R, Graveron-Demilly D. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. *Comput Biol Med* 2001;31:269-286.
16. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. *Can Med Assoc J* 1985;132:919-923.
17. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. *J Gerontol* 1994;49:M85-94.
18. Sergi G, De Rui M, Veronese N, Bolzetta F, Berton L, Carraro S et al. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. *Clin Nutr* 2015;34:667-673.
19. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery - A report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 2002;39(2):257-265.
20. Szende A, Oppe M, Devlin N. Inventory, Comparative Review and User Guide. In: EQ-5D Value Sets. Dordrecht: Springer; 2007.
21. Khan F, Ray S, Craigie AM, Kennedy G, Hill A, Barton KL et al. Lowering of oxidative stress improves endothelial function in healthy subjects with habitually low intake of fruit and vegetables: A randomized controlled trial of antioxidant- and polyphenol-rich blackcurrant juice. *Free Radic Biol Med* 2014;72:232-237.

22. Perera S, Mody SH, Woodman RC, Studenski SA. Meaningful change and responsiveness in common physical performance measures in older adults. *J Am Geriatr Soc* 2006;54:743-749.
23. Sautin YY, Johnson RJ. Uric acid – the oxidant-antioxidant paradox. *Nucleosides nucleotides nucleic acids* 2008;27:608-619.
24. Hershfield MS, Roberts LJ, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. *Proc Natl Acad Sci USA* 2010;107:14351-14356.
25. Gingles CR, Symon R, Gandy SJ, Struthers AD, Houston G, MacDonald TM et al. Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension. *J Hypertens* 2019;37:2481-2489
26. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. *J Am Soc Nephrol* 2011;22:1382-1389.
27. Wray DW, Nishiyama SK, Donato AJ, Carlier P, Bailey DM, Uberoi A et al. The paradox of oxidative stress and exercise with advancing age. *Exerc Sport Sci Rev* 2011;39:68-76.
28. Vina J, Gimeno A, Sastre J, Desco C, Asensi M, Pallardo FV et al. Mechanism of free radical production in exhaustive exercise in humans and rats; role of xanthine oxidase and protection by allopurinol. *IUBMB Life* 2000;49:539-544
29. dos Santos MR, Saitoh M, Ebner N, Valentova M, Konishi M, Ishida J et al. Sarcopenia and endothelial function in patients with chronic heart failure: Results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). *J Am Med Dir Assoc* 2017;18:240-245.

30. Settle T, Falkenstein E, Klandorf H. The effect of allopurinol administration on mitochondrial respiration and gene expression of xanthine oxidoreductase, inducible nitric oxide synthase, and inflammatory cytokines in selected tissues of broiler chickens. *Poult Sci* 2015;94:2555-2565.

**Table 1.** Baseline details

		Allopurinol (n=62)	Placebo (n=62)	p
Mean age (years) (SD)		79.9 (5.3)	80.6 (6.6)	0.55
Female sex (%)		29 (47)	30 (48)	0.86
Ischaemic heart disease (%)		8 (13)	12 (19)	0.33
Hypertension (%)		42 (68)	33 (53)	0.10
Dyslipidaemia (%)		34 (55)	33 (53)	0.86
Stroke or TIA (%)		7 (11)	6 (10)	0.77
Diabetes mellitus (%)		10 (16)	10 (16)	1.00
Median weekly alcohol intake (units) (IQR)		2 (1 – 8)	2 (0 – 5)	0.38
Current smoker (%)		3 (5)	5 (8)	0.47
Systolic blood pressure (mmHg) (SD)		141 (15)	146 (20)	0.14
Diastolic blood pressure (mmHg) (SD)		78 (10)	76 (10)	0.49
Body Mass Index (kg/m <sup>2</sup> ) (SD)		28.5 (4.6)	28.1 (4.9)	0.59
Six minute walk distance (m)		295 (80)	290 (79)	0.75
Muscle mass (kg) (SD)	Males	11.6 (2.3)	11.2 (2.4)	0.50
	Females	9.9 (1.8)	10.1 (1.6)	0.72
Short physical performance battery (SD)		8.6 (2.0)	8.4 (2.0)	0.69
Median total number of medications (IQR)		5 (3 – 8)	5 (3 – 8)	0.90
Medications:				

Angiotensin converting enzyme inhibitor	15 (24)	17 (27)	0.68
Beta blocker	9 (15)	12 (19)	0.47
Calcium channel blocker	22 (35)	17 (27)	0.33
Alpha blocker	7 (11)	5 (8)	0.76
Thiazide	14 (23)	15 (24)	0.83
Loop diuretic	5 (8)	5 (8)	1.00
Aldosterone antagonist	2 (3)	2 (3)	1.00
Angiotensin receptor blocker	6 (10)	5 (8)	0.75
Statin	29 (47)	23 (37)	0.28
Antiplatelet	14 (23)	16 (26)	0.68
Insulin	2 (3)	0 (0)	0.50
Antidiabetic	6 (10)	6 (10)	1.00

Independent t-test, Mann-Whitney test or Pearsons chi-squared (Fisher's exact where cell value <5

**Table 2.** Primary outcome – effect of treatment on measures of phosphocreatine recovery rate

		Allopurinol (median, IQR)	Placebo (median, IQR)	Treatment effect* (95% CI)	p
Normalised ViPCr	Baseline	0.50 (0.33-0.83)	0.60 (0.35-0.78)	0.10 (-0.07 to 0.27)	0.25
	20 weeks	0.60 (0.33-0.94)	0.59 (0.43-0.82)		
<i>Sensitivity analyses</i>					
Normalised ViPCr – multiply imputed				0.08	0.36
				(-0.09 to 0.26)	
Normalised ViPCr – per protocol	Baseline	0.50 (0.31-0.99)	0.54 (0.32-0.76)	0.10 (-0.07 to 0.27)	0.27
	20 weeks	0.63 (0.36-0.96)	0.58 (0.43-0.82)		
Un- normalised ViPCr	Baseline	23385 (5419-38668)	20681 (3821-33521)	5715	0.23
	20 weeks	28227 (16818-51171)	29005 (17810-42279)	(-3674 to 15104)	

ViPCr: Initial rate of phosphocreatine recovery

\*Estimated marginal mean from generalised linear model using gamma distribution with log link

Multiple imputation: using baseline ViPCr, age, sex, baseline six min walk and SPPB to impute missing ViPCr. 10 imputations

**Table 3.** Secondary outcomes

		Allopurinol (SD)	Placebo (SD)	Treatment effect (95% CI)	p
Six minute walk (m)	Baseline	295 (80)	290 (79)	25 (4 to 46)	0.02
	20 weeks	366 (95)	340 (85)		
Lean body mass (kg/m <sup>2</sup> )	Baseline	10.8 (2.3)	10.7 (2.1)	0.1 (-0.5 to 0.7)	0.70
	20 weeks	10.6 (2.0)	10.4 (2.0)		
SPPB	Baseline	8.6 (2.0)	8.4 (2.0)	0.0 (-0.5 to 0.5)	0.91
	20 weeks	9.3 (1.8)	9.1 (1.9)		
EQ5D health state	Baseline	0.78 (0.20)	0.77 (0.23)	0.02 (-0.03 to 0.07)	0.41
	20 weeks	0.81 (0.14)	0.80 (0.20)		
EQ5D thermometer	Baseline	78 (15)	78 (14)	2 (-2 to 6)	0.32
	20 weeks	79 (14)	78 (13)		
Systolic BP (mmHg)	Baseline	141 (15)	146 (20)	0 (-5 to 5)	0.94
	20 weeks	143 (15)	145 (17)		
Diastolic BP (mmHg)	Baseline	78 (10)	76 (10)	-1 (-4 to 2)	0.66
	20 weeks	76 (10)	76 (11)		



FMD* (%)	Baseline	7.50 (3.86)	7.59 (3.95)	-0.63 (-2.11 to 0.84)	0.39
	20 weeks	6.92 (3.07)	7.45 (3.69)		
FMD GTN (%)	Baseline	14.88 (5.55)	17.09 (5.50)	2.23 (-0.57 to 5.03)	0.12
	20 weeks	16.37 (5.30)	15.25 (6.64)		
Urate (mmol/L)	Baseline	0.38 (0.14)	0.42 (0.14)	-0.12 (-0.16 to 0.08)	<0.001
	20 weeks	0.24 (0.16)	0.40 (0.15)		
TBARS (uM)	Baseline	2.94 (1.51)	3.09 (1.34)	0.09 (-0.38 to 0.56)	0.70
	20 weeks	3.10 (1.68)	3.18 (1.51)		
8OHDG	Baseline	254 (107)	251 (104)	23 (-4 to 50)	0.10
	20 weeks	292 (140)	258 (104)		

8OHDG: 8-hydroxydeoxyguanosine. BP: Blood pressure. EQ5D: EuroQoL 5 dimension

score. FMD: Flow-mediated dilatation of the brachial artery. GTN: Glyceryl trinitrate. SPPB:

Short physical performance battery. TBARS: Thiobarbiturate Reactive Substances

\*n=43 for each group at baseline

Treatment effects adjusted for baseline value of variable under test

Figure legends:

Figure 1: CONSORT diagram of participant flow through the trial